Clinical Correlates and Outcomes of Methamphetamine-Associated Cardiovascular Diseases in Hospitalized Patients in

Lara Curran1, Gregory Nah1, Gregory M Marcus1

  • 1Department of Medicine Division of Cardiology, University of California San Francisco San Francisco CA.

Insights

Methamphetamine use significantly increases cardiovascular disease (CVD) risk, comparable to alcohol and cocaine. Key risk factors among users include chronic kidney disease, hypertension, and mental health disorders.

Area of Science:

  • Cardiology
  • Public Health
  • Addiction Medicine

Background:

  • Methamphetamine misuse affects millions globally, with known links to cardiovascular disease (CVD).
  • Risk factors for CVD among methamphetamine users remain understudied.
  • Understanding these risks is crucial for targeted prevention and treatment strategies.

Purpose of the Study:

  • To investigate the association between methamphetamine use and the development of CVD.
  • To identify specific risk factors for CVD in methamphetamine users.
  • To compare the CVD risk associated with methamphetamine use to that of other substance use disorders.

Main Methods:

  • Analysis of hospitalized patients from the Healthcare Cost and Utilization Project database (2005-2011).
  • Inclusion of over 20 million individuals, with a focus on 66,199 methamphetamine users.
  • Statistical analysis to determine hazard ratios (HR) for CVD events, including heart failure, pulmonary hypertension, stroke, and myocardial infarction.

Main Results:

  • Methamphetamine use was associated with increased risk of heart failure (HR 1.53) and pulmonary hypertension (HR 1.42).
  • Male sex, chronic kidney disease (HR 2.38), and hypertension (HR 2.26) were significant risk factors for CVD among users.
  • Methamphetamine use showed a 32% increase in CVD risk, similar to alcohol (28%) and cocaine (47%).

Conclusions:

  • Methamphetamine use poses a substantial risk for cardiovascular disease, on par with alcohol and cocaine abuse.
  • Individuals with co-occurring chronic kidney disease, hypertension, and mental health disorders are particularly vulnerable.
  • Clinical interventions should prioritize these high-risk groups for CVD prevention and management.

Related Concept Videos

Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
29
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
19
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
46
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
21
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids01:24

CNS Stimulants: Cocaine, Amphetamines and Cannabinoids

CNS stimulants, such as cocaine, amphetamines, and cannabinoids, have varying structures and mechanisms of action that lead to different therapeutic effects and side effects. Cocaine, with its molecular formula C17H21NO4, is a tropane alkaloid and a tertiary amino compound. It has two chemical forms: the hydrochloride salt and the "freebase." The former is in powder form, while the latter involves removing the hydrochloride salt to create a form that can be smoked. Cocaine exerts its...
321
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
42